Jul 11: German based pharma major Boehringer Ingelheim and Mumbai-based Lupin Ltd on Wednesday announced the expansion of their partnership with plans to market two new oral anti-diabetics recently approved by the Drugs Controller General of India (DCGI) – Gibtulio Met (Empagliflozin + Metformin) and Ajaduo (Empagliflozin + Linagliptin).
According to a Lupin statement, both these products belong to a novel class of oral anti-diabetic drugs patented in India and will be launched for the first time by an Indian company. The two products will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names.
The Indian diabetes market is valued at Rs 1,13,360 million and is growing at 11.7% (IMS MAT April 2018) with the oral anti-diabetic market being valued at Rs 83,340 million and growing at 11.21% (IMS MAT April 2018).
Commenting on the expanded partnership, Sharad Tyagi, Managing Director – Boehringer Ingelheim India said, “we are pleased to expand this partnership and work closely with Lupin, to provide wider access and innovative solutions towards better diabetes management in India. With this, the medical fraternity and patients will now have access to one of the most comprehensive Diabetes portfolios in the country. As a dedicated organization to the field of diabetes, we aim to reinforce our commitment by continually exploring newer avenues to help reduce the diabetes burden in the country.”